Skip to content

Doxycycline cures non-infective-nonmalignant lung lessions.

Role of doxycycline in treating different tissue lesions and thickening of lung and pleura: a pilot case based observation with different types of lesions.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/10/004080
Enrollment
30
Registered
2013-10-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- with different lung lesions

Interventions

Intervention1: Doxycycline: 100 mg BD for body weight over 45kg and 100 mg OD for body weight less than 45kg. route of administration- Orally. Intervention2: Doxycycline 100 mg: Doxycycline 100 mg BD

Sponsors

Dr Parthasarathi Bhattacharyya
Lead Sponsor
Institute of Pulmocare and Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing to give written informed consent 2. Male/Female of age 15-75 years with lung and pleural lesion as described in protocol.

Exclusion criteria

Exclusion criteria: 1. active infection or malignancy will be excluded. 2. unable to meet the demand of the protocol for any reason. 3. significant abnormality in liver and renal function 4. features of chronic congestive cardiac failure (supported by echocardiography) 5. history of exacerbation in past 1 month

Design outcomes

Primary

MeasureTime frame
to see the long term doxycycline in different variety of lung lesions without overt symptoms and/or evidence of active co presence of infection/malignancyTimepoint: Nil

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Parthasarathi Bhattacharyya

Institute of Pulmocare and Research, Kolkata

parthachest@yahoo.com033-23580424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026